INKT · Mink Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $5.76M | $6.34M | $15.49M | $23.12M | $9.51M |
| SG&A | $6.73M | $4.31M | $7.43M | $7.83M | $1.29M |
| Total Operating Expenses | - | - | - | - | - |
| D&A | $181.7K | $215.4K | $204.6K | $121.7K | $55.1K |
| Operating Income | ($12.64M) | ($11.29M) | ($22.92M) | ($30.95M) | ($14.64M) |
| Interest Expense | ($110.0K) | ($93.0K) | - | - | $2.44M |
| Income Tax | - | - | - | - | - |
| Net Income | ($12.49M) | ($10.78M) | ($22.46M) | ($27.99M) | ($16.24M) |
| EPS - Basic | ($2.93) | ($2.86) | ($6.50) | ($8.30) | - |
| EPS - Diluted | ($2.93) | ($2.86) | ($6.50) | ($8.30) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $13.36M | $4.58M | $3.37M | $19.64M | $38.89M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $3.43M | $2.73M | $3.91M | $5.82M | $3.00M |
| Current Assets | $13.85M | $4.99M | $3.60M | $20.40M | $39.63M |
| Total Assets | $14.24M | $5.72M | $4.55M | $21.47M | $40.24M |
| Current Liabilities | $13.03M | $6.96M | $11.40M | $12.68M | $16.47M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Stockholders' Equity | ($14.23M) | ($19.59M) | ($18.06M) | ($401.3K) | $23.78M |
| Retained Earnings | ($156.68M) | ($144.18M) | ($133.40M) | ($110.94M) | ($82.95M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($5.93M) | ($9.56M) | ($15.76M) | ($18.87M) | ($8.34M) |
| Investing Cash Flow | - | - | ($73.6K) | ($250.0K) | ($95.2K) |
| Financing Cash Flow | $14.72M | $10.82M | ($407.2K) | ($155.6K) | $11.11M |
| CapEx | - | - | $73.6K | $250.0K | $95.2K |
| Free Cash Flow | - | - | ($15.84M) | ($19.12M) | ($8.43M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | 0.71 | 0.68 | 0.52 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -87.7% | -188.5% | -493.3% | -130.4% | -40.4% |
| Return on equity | 87.8% | 55.1% | 124.4% | 6975.1% | -68.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
| Quick ratio | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
| Cash ratio | 1.03 | 0.66 | 0.30 | 1.55 | 2.36 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | 114.9x | 121.4x | - | - | -6.0x |
| Equity multiplier | -1.00 | -0.29 | -0.25 | -53.50 | 1.69 |
| Liabilities / Assets | - | - | - | - | - |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -12.0% | 50.8% | 25.9% | -111.4% | - |
| Net income growth (YoY) | -15.9% | 52.0% | 19.8% | -72.4% | - |
| EPS growth (YoY) | -2.4% | 56.0% | 21.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | 17.2% | -126.7% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 27.4% | -8.5% | -4399.2% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing MiNK Therapeutics against the 5 most active filers in the same SIC group.